AI assistant
REPLIGEN CORP — Director's Dealing 2025
Mar 19, 2025
30826_dirs_2025-03-19_eb614f66-a621-4450-9091-6028e3f01191.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: REPLIGEN CORP (RGEN)
CIK: 0000730272
Period of Report: 2025-03-17
Reporting Person: Hunt Anthony (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-03-17 | Common Stock | M | 5000 | $33.87 | Acquired | 141301 | Direct |
| 2025-03-17 | Common Stock | M | 21756 | $59.52 | Acquired | 163057 | Direct |
| 2025-03-17 | Common Stock | S | 60 | $148.05 | Disposed | 162997 | Direct |
| 2025-03-17 | Common Stock | S | 100 | $150.38 | Disposed | 162897 | Direct |
| 2025-03-17 | Common Stock | S | 2518 | $151.09 | Disposed | 160379 | Direct |
| 2025-03-17 | Common Stock | S | 6176 | $151.96 | Disposed | 154203 | Direct |
| 2025-03-17 | Common Stock | S | 15619 | $152.82 | Disposed | 138584 | Direct |
| 2025-03-17 | Common Stock | S | 2283 | $153.7 | Disposed | 136301 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-03-17 | Stock Option (Right to Buy) | $33.87 | M | 5000 | Disposed | 2028-03-01 | Common Stock (5000) | Direct |
| 2025-03-17 | Stock Option (Right to Buy) | $59.52 | M | 21756 | Disposed | 2029-02-28 | Common Stock (21756) | Direct |
Footnotes
F1: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2024.
F2: $148.05 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.01 to $148.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: $151.09 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.42 to $151.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4: $151.96 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.43 to $152.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5: $152.82 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.39 to $153.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range
F6: $153.70 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.55 to $153.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F7: 207,344 of the shares underlying this option have vested. The remaining shares vest as follows: 28,777 shares on March 1, 2026, and 28,778 shares on March 1, 2027.
F8: This option is fully vested and exercisable.